Estradiol in non-oral hormonal contraception: a “long and winding road”

@article{Grandi2019EstradiolIN,
  title={Estradiol in non-oral hormonal contraception: a “long and winding road”},
  author={G. Grandi and F. Barra and S. Ferrero and F. Facchinetti},
  journal={Expert Review of Endocrinology \& Metabolism},
  year={2019},
  volume={14},
  pages={153 - 155}
}
The pill [combined oral contraceptive (COC)], with around 140 million of users worldwide, is the most popular method of contraception and the most used ‘chronic therapy’ by women before the age of 40, period of life in which they are generally healthy. The traditional COC has exclusively contained ethinylestradiol (EE) in decreasing doses for about 50 years. The introduction of estradiol (E2) alongside EE started in 2009 by oral route, with the original aim of reducing the metabolic impact and… Expand
The paradigm of norgestimate: a third-generation testosterone-derivative progestin with a peripheral anti-androgenic activity and the lowest risk of venous thromboembolism
TLDR
A narrative review of the available data on the pharmacotherapy of NGM in combined hormonal contraceptives (CHCs) in terms of contraceptive efficacy, venous thromboembolism risk, safety, tolerability and bleeding patterns is reviewed. Expand
Combined hormonal contraception and COVID-19
  • I. Lete
  • Medicine
  • The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception
  • 2021
TLDR
The factors that protect women from the severity of the disease are analysed, as well as the risk factors for the use of this type of contraception, especially related to the increased risk of a thrombotic event in patients affected by the disease. Expand
Surface roughness of different contraceptive vaginal rings: evaluation by scanning electron microscope (SEM)
TLDR
The different composition of the vaginal rings’ EVA membrane is not associated with different surface roughness, and Ornibel is equivalent to NuvaRing in terms of surface Roughness, despite the different compositions of the membrane polymers. Expand

References

SHOWING 1-10 OF 20 REFERENCES
Metabolic impact of combined hormonal contraceptives containing estradiol
TLDR
The preliminar parenteral use of E2 seems promising, both transdermal and vaginal, in particular after the introduction of a specific progestin with a high anti-ovulatory activity, like nestorone. Expand
Review of clinical experience with estradiol in combined oral contraceptives.
TLDR
More recent studies employing endometrial-focused progestins, e.g., DNG, and multiphasic dosing regimens appear to be a promising approach for an E2-based COC that provides efficient ovulation inhibition and acceptable cycle control. Expand
Impact of estrogen type on cardiovascular safety of combined oral contraceptives.
TLDR
DNG/EV is associated with similar or even lower cardiovascular risk compared to oCOC and LNG, particularly levonorgestrel-containing COCs (LNG) and other progestogens. Expand
Biological effects of estradiol-17 beta in postmenopausal women: oral versus percutaneous administration.
TLDR
It is suggested that the route of administration of E2 determines the biochemical response to ERT in postmenopausal women and SBP is the most sensitive marker of the liver action of estrogen, and triglycerides also are simple and useful markers for this effect. Expand
Haemostatic and metabolic impact of estradiol pills and drospirenone-containing ethinylestradiol pills vs. levonorgestrel-containing ethinylestradiol pills: A literature review
  • I. Lete, N. Chabbert-Buffet, +4 authors A. Pintiaux
  • Medicine
  • The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception
  • 2015
TLDR
E2/NOMAC exhibits less haemostatic and metabolic impact than EE/LNG and other COCs, suggesting that it may be a promising candidate to reduce residual VTE risk associated with COC use. Expand
Pituitary, ovarian and additional contraceptive effects of an estradiol-based combined oral contraceptive: results of a randomized, open-label study.
TLDR
E(2)V/DNG provides extraovarian contraceptive effects (reducing endometrial thickness and cervical mucus production) in addition to inhibiting ovulation, assuring contraceptive efficacy. Expand
Phase II dose-finding study on ovulation inhibition and cycle control associated with the use of contraceptive vaginal rings containing 17β-estradiol and the progestagens etonogestrel or nomegestrol acetate compared to NuvaRing
  • I. Duijkers, C. Klipping, +4 authors T. Korver
  • Medicine
  • The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception
  • 2018
TLDR
While non-inferiority to NuvaRing® was not met, among the investigational rings, the ENG-E2 125/300 ring provided the best cycle control and are generally well-tolerated. Expand
Continuous dosing of a novel contraceptive vaginal ring releasing Nestorone® and estradiol: pharmacokinetics from a dose-finding study.
BACKGROUND As part of a program to develop a novel estradiol-releasing contraceptive vaginal ring (CVR), we evaluated the pharmacokinetic (PK) profile of CVRs releasing segesterone acetateExpand
Can changes in sex hormone binding globulin predict the risk of venous thromboembolism with combined oral contraceptive pills?
TLDR
The aim of this article is to discuss sex hormone binding globulin (SHBG) as a marker of estrogenicity and as a surrogate indicator for the potential risk of VTE in users of COC. Expand
Hormonal contraception in women with endometriosis: a systematic review
  • G. Grandi, F. Barra, +4 authors F. Facchinetti
  • Medicine
  • The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception
  • 2019
TLDR
CHCs and POCs are effective for the relief of endometriosis-related dysmenorrhoea, pelvic pain and dyspareunia, and improve QoL, with insufficient evidence, however, to reach definitive conclusions about the overall superiority of any particular hormonal contraceptive. Expand
...
1
2
...